Labrys Biologics

Labrys Biologics was a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Mateo, California, developing monoclonal antibody therapeutics targeting calcitonin gene-related peptide (CGRP) for the prevention of chronic and episodic migraine. The company was venture-backed, with Canaan Partners among its investors, and was acquired by Teva Pharmaceutical Industries in 2014, after which its lead anti-CGRP antibody program continued under Teva. Labrys Biologics no longer operates as an independent company and maintains no developer or API surface: enrichment probes on 2026-07-19 found the registrant domain labrysbiologics.com resolving but serving nothing (TCP 80 and 443 closed), delegated to Teva nameservers, with a no-mail SPF/DMARC lockdown and no GitHub organization. This profile is retained as a historical portfolio-company record rather than an API listing.

Labrys Biologics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Therapeutics.

🌐 Visit website 📡 Source on GitHub
3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesTherapeuticsNeurologyClinical ResearchAcquired

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 3.3/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/labrys-biologics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Labrys Biologics Domain Security

DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Source (apis.yml)

apis.yml Raw ↑ 
aid: labrys-biologics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/labrys-biologics.png
name: Labrys Biologics
description: 'Labrys Biologics was a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Mateo,
  California, developing monoclonal antibody therapeutics targeting calcitonin gene-related peptide (CGRP) for the prevention
  of chronic and episodic migraine. The company was venture-backed, with Canaan Partners among its investors, and was acquired
  by Teva Pharmaceutical Industries in 2014, after which its lead anti-CGRP antibody program continued under Teva. Labrys
  Biologics no longer operates as an independent company and maintains no developer or API surface: enrichment probes on 2026-07-19
  found the registrant domain labrysbiologics.com resolving but serving nothing (TCP 80 and 443 closed), delegated to Teva
  nameservers, with a no-mail SPF/DMARC lockdown and no GitHub organization. This profile is retained as a historical portfolio-company
  record rather than an API listing.'
url: https://raw.githubusercontent.com/api-evangelist/labrys-biologics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: teva
x-acquired-year: 2014
x-operating: false
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Therapeutics
- Neurology
- Clinical Research
- Acquired
apis: []
common:
- type: DomainSecurity
  url: security/labrys-biologics-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence